The long-expected approval of Vertex Pharmaceuticals’ new combination drug for cystic fibrosis is finally here. The FDA approved the therapy regimen in a letter it sent to the Boston-based company Thursday.
The drug’s approval was all but certain, and paves the way for potential billions of dollars in future sales. Vertex plans to sell it under the brand name Orkambi.
In-body microchips that deliver medicine in doses either pre-determined or controlled by doctors from outside the body could be the next big thing in drug delivery, and Teva Pharmaceuticals has jumped onto the bandwagon.
The company announced last week a new partnership with US firm Microchips Biotech to deliver Teva-made drugs to patients using the American company’s implanted microchip. It’s the first deal for Microchips Biotech – and the first ever that seeks to commercialize what some consider to be a controversial technology.
Venture capital-backed healthcare startups are addressing diseases and conditions affecting virtually every part of the human body.
Tech isn’t the only sector receiving billions in venture capital funding. Healthcare and life sciences companies raised more than $8B from VC firms in 2014. And while tech exits may have slowed down, exits of VC-baked healthcare startups have been strong, especially IPOs: there were 61 in 2014 alone.
es chercheurs de l'Université de Göttingen (UMC - Basse-Saxe) ont développé un biocapteur fournissant des informations sur les mécanismes de l'insuffisance cardiaque dans des organismes vivants. Leurs travaux sont financés par l'Agence allemande de moyens pour la recherche (DFG), dans le cadre de l'unité de recherche spécifique 1002 "unités modulaires pour l'insuffisance cardiaque" (SFB 1002 "Modulatorische Einheiten bei Herzinsuffizienz")
There are several long-term studies taking place around the world to track the health of large groups of people. One in Seattle called the 100K Wellness Project is spinning out a new company called Arivale with a caffeinated jolt of local investment cash.
Health technology startup Healthfinch has grown from four employees to 21 since January 2014. How? By selling software that saves doctors time, letting them spend more of their day with patients.
Nivalis Therapeutics, a Boulder, CO-based drug company developing a treatment for cystic fibrosis, made its debut on the Nasdaq on Wednesday with a $77 million public offering.
Le projet VascuBone s'est conclu fin mars après cinq ans de travail. Les objectifs du projet étaient : - d'optimiser les substituts osseux, afin de diminuer le risque de rejet, - de favoriser la capacité de régénération propre de l'organisme, - de stimuler la croissance osseuse.
19 partenaires de quatre pays ont participé à ce projet, financé par l'Union européenne et coordonné par l'Institut Fraunhofer pour le génie des interfaces et les procédés biotechnologiques (IGB). Le résultat du projet est la "Toolbox VascuBone", une sorte de kit comprenant plusieurs composants pour la régénération osseuse.
